Treatment of refractory acute leukaemia with aclacinomycin A.
Rowe
J M
JM
University of Rochester Medical Center, NY.
Chang
A Y
AY
Bennett
J M
JM
D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D005047:Etoposide; D015250:Aclarubicin